Clinica Baviera (XMAD:CBAV) 3-Year RORE % : 13.44% (As of Mar. 2026)


XMAD:CBAV Clinica Baviera SA XMAD:CBAV
100 GF Score
Price €59.40
GF Value €41.36
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Clinica Baviera 3-Year RORE %?

Clinica Baviera XMAD:CBAV +1.37% 100 3-Year RORE % is 13.44 as of Mar. 2026. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.36 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 69.8% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Clinica Baviera's 3-Year RORE % for the quarter that ended in Mar. 2026 was 13.44%.

The industry rank for Clinica Baviera's 3-Year RORE % or its related term are showing as below:

XMAD:CBAV's 3-Year RORE % is ranked better than
69.8% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.935 vs XMAD:CBAV: 13.44

Clinica Baviera  (XMAD:CBAV) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Clinica Baviera 3-Year RORE % Related Terms


Clinica Baviera 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Clinica Baviera's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinica Baviera 3-Year RORE % Chart

Clinica Baviera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.02 42.20 18.72 21.84 12.39

Clinica Baviera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.34 22.71 23.36 12.39 13.44

XMAD:CBAV vs TMO, DHR, IDXX: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Clinica Baviera's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinica Baviera 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Clinica Baviera's 3-Year RORE % falls into.


XMAD:CBAV
100GF Score
Clinica Baviera SA XMAD:CBAV
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinica Baviera 3-Year RORE % Calculation

Clinica Baviera's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 2.739-2.257 )/( 7.526-3.94 )
=0.482/3.586
=13.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 13.44 mean?
Clinica Baviera (XMAD:CBAV) has a 3-Year RORE % of 13.44 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Clinica Baviera and its competitors. According to the industry distribution chart, Clinica Baviera ranks #61 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 30.2%.
Is Clinica Baviera's 3-Year RORE % too high?
Clinica Baviera's current 3-Year RORE % is 13.44. Based on the distribution chart, Clinica Baviera ranks #61 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #61 out of 202 companies for 3-Year RORE %. This puts Clinica Baviera in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Clinica Baviera and its competitors. Clinica Baviera's current 3-Year RORE % is 13.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.36, compared to a current price of €59.40 — trading 43.6% above its estimated fair value. The current 3-Year RORE % is 13.44. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current 3-Year RORE % is 13.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued. The current stock price of €59.40 is trading 43.6% above its estimated GF Value™ of €41.36. GuruFocus considers Clinica Baviera to be Significantly Overvalued.

Key valuation signals for XMAD:CBAV:

  • 3-Year RORE %: 13.44
  • GF Value™: €41.36 vs. price of €59.40 (43.6% above fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clinica Baviera Business Description

Other Exchanges 0GWJ:UKD9Z:Germany
Address Paseo de la Castellana 20, Madrid, ESP, 28046
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score

Get the complete analysis for XMAD:CBAV

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€59.40
Price
€41.36
GF Value